GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer

Colorectal cancer stage III Inclusion Criteria: * Colorectal cancer, UICC stage III * Has received curative-intent resection and is a candidate for adjuvant chemotherapy * Patient able to understand and sign written informed consent Exclusion Criteria: * Hereditary colorectal cancer linked to familial colonic polyposis or Lynch syndrome * Inflammatory bowel disease (Crohn's disease or ulcerative colitis) * Verified distant metastases * Not treated with adjuvant chemotherapy despite indication (incomplete treatment not included) * Treated with neoadjuvant chemo-radiation therapy * No tissue sample available for the project, or tumor content in the tissue sample is \<20% * Synchronous colorectal and non-colorectal cancer diagnosed per operative (except skin cancer other than melanoma) * Other cancers (excluding colorectal cancer or skin cancer other than melanoma) within 3 years from eligibility screening * Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study Colorectal cancer liver metastasis Inclusion Criteria: * Colorectal cancer liver metastasis * Planned for curative-intent treatment * Performance status 0-1 Exclusion Criteria: * Liver cirrhosis * Extrahepatic metastases * Other cancer within the last 5 years * Intervention not performed with curative intent * No tissue available from CRLM or primary tumor